News

HSBC Picks 10 Stocks to Watch as Earnings Season Begins

West Pharmaceutical Services (NYSE:WST) has sold the rights and facilities related to its SmartDose 3.5 mL On Body Delivery System to AbbVie. The transaction shifts ownership of this specific large volume wearable injector platform while allowing West Pharmaceutical Services to focus on other drug delivery offerings. The deal reflects a change in how NYSE:WST is positioning its portfolio within the drug delivery and pharmaceutical packaging market. West Pharmaceutical Services operates in...

JNJ and AbbVie both beat revenue expectations in Q1 2026, yet their strategies could not look more different, and which playbook actually wins depends entirely on what kind of investor you are.

This healthcare giant is on a serious run, but for investors arriving now, the question is whether the price of admission already includes the victory lap.

Big pharma is funding a field it once dismissed. These three psychedelic stocks carry possible clinical catalysts as the healthcare industry turns to alternative medicines.

In the closing of the recent trading day, AbbVie (ABBV) stood at $249.91, denoting a -1.12% move from the preceding trading day.

Get paid a guaranteed income now on your Amgen shares, which you keep no matter what, in exchange for agreeing to sell at a price that's already a win.

AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.

West Pharmaceutical completes the SmartDose 3.5mL sale to AbbVie, sharpening its focus on higher-growth on-body drug delivery technologies.

FTSE 100 Live pre-open Blue-chip stocks in London and mainland Europe are set to rebound on Thursday after reports that the US and Iran could agree a new ceasefire deal. FTSE 100 futures pointed to a gain of 36 points, a day after the index plunged almost 177 points to end...

SLS009 traces back to Sellas’ 2022 GenFleet licensing deal, when the company obtained rights outside Greater China to GFH009, now known as SLS009.

Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri

For shareholders, the coming year isn't about a small gain or loss but a potential journey to one of two very different destinations.

The battle between JPMorgan’s two flagship covered-call income ETFs comes down to a simple trade-off: JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) offers the smoother ride, while JPMorgan Nasdaq Equity Premium Income ETF (NASDAQ:JEPQ) delivers the fatter distributions. In July 2026, that trade-off looks less balanced than usual, and the winner may not be the one ... JEPI vs. JEPQ: Which Is the Better Buy in July?

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th

Five Dividend Kings—Procter & Gamble, Hormel, Stanley Black & Decker, Genuine Parts and Lowe's—trade at discounted valuations, offering attractive yields despite near-term business headwinds.

AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

AbbVie (ABBV) is back in focus after the European Commission granted marketing authorization for Tepkinly plus lenalidomide and rituximab in relapsed or refractory follicular lymphoma, a chemotherapy free bispecific-based regimen for second line treatment. See our latest analysis for AbbVie. Against this backdrop of oncology approvals and index inclusions, AbbVie’s recent momentum is clear, with a 30 day share price return of 12.07% and a 90 day share price return of 20.35%, while 1 year...

While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.

Abivax stock surged over 40% after positive Phase 3 data on ulcerative colitis drug Obefazimod and a $920 million share offering that underwriters fully exercised, signaling strong institutional demand.

Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, royalties and broader pipeline momentum.

AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.

It doesn't get much more dependable and lucrative than the healthcare industry.

(Updates with stock and oil price moves, and additional details from sixth paragraph onward.) US

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.

Dividend Aristocrats, the S&P 500 companies that have raised payouts for 25 or more consecutive years, remain the bedrock of income portfolios heading into the second half of 2026. Three of them stand out for July: a beaten-down quick-service leader, a biopharma machine firing on all cylinders, and a home improvement giant priced for a ... 3 Dividend Aristocrats to Buy in July

Look for history to repeat itself with Apple's latest pullback.

While rivals scramble to replace lost revenue, Lilly is opening an unprecedented gap by being a “contrarian,” as one expert says.

Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of, and it was the clearest sign a surge was building.

Dividend funds pulled in $24.1 billion in the first quarter of 2026, their strongest opening quarter in four years, and a lot of that cash went looking for a boring place to hide from AI-hype exhaustion. The iShares Core High Dividend ETF (NYSEARCA:HDV) is one of them. HDV holds 75 positions, charges 0.08%, and yields ... A 2.86% Yield, 0.08% Fee, and 75 Stocks: Is HDV the Anti-Hype ETF?